Brief: Royalty Pharma Announces Research And Development Funding Collaboration For Chronic Immune-Mediated Diseases
30/03/2026 14:20
March 30 (Reuters) - Royalty Pharma PLC RPRX.O: ROYALTY PHARMA ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING COLLABORATION FOR CHRONIC IMMUNE-MEDIATED DISEASES ROYALTY PHARMA - ANNOUNCES $500 MILLION RESEARCH AND DEVELOPMENT CO-FUNDING AGREEMENT WITH JOHNSON & JOHNSON FOR 2026-2027 ROYALTY PHARMA - AGREEMENT TO ADVANCE DEVELOPMENT OF JNJ-4804 FOR AUTOIMMUNE DISEASES Source text: ID:nGNX7wjM4q Further company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsBrief: Royalty Pharma - Enters Revolving Credit Agreement On May 22, 2026
Royalty Pharma Q1 adjusted EBITDA misses analyst estimates
Zymeworks rises after naming new CFO
Zymeworks rises after naming new CFO
Brief: Royalty Pharma Announces Research And Development Funding Collaboration For Chronic Immune-Mediated Diseases